TFF1/pS2 Antibody (GE2 (same as R47/94)), DyLight 550, Novus Biologicals™

Mouse Monoclonal Antibody

Supplier:  Novus Biologicals NBP234623R

Catalog No. NBP234623R

Description

TFF1/pS2 Monoclonal specifically detects TFF1/pS2 in Human, Cynomolgus Monkey samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin.

Specifications

• Antigen: TFF1/pS2
• Classification: Monoclonal
• Conjugate: DyLight 550
• Gene Alias: BCEIbreast cancer, estrogen-inducible sequence expressed in, Breast cancer estrogen-inducible protein, breast cancer estrogen-inducible sequence, D21S21, gastrointestinal trefoil protein pS2, hP1.A, HPS2, pNR-2, Polypeptide P1.A, Protein pS2, pS2, trefoil factor 1, trefoil factor, BCE1, human pS2 induced by estrogen from human breast cancercell line M10HP1.A
• Host Species: Mouse
• Molecular Weight of Antigen: 6.5 kDa
• Quantity: 0.1 mL
• Research Discipline: Breast Cancer, Cancer
• Gene ID (Entrez): 7031
• Target Species: Human, Primate
• Form: Purified

• Applications: Western Blot, Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)
• Clone: GE2 (same as R47/94)
• Dilution: Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen
• Gene Symbols: TFF1
• Immunogen: A synthetic peptide (around aa 57-84) of human TFF1/pS2 polypeptide (exact sequence is proprietary) (Uniprot: P04155)
• Purification Method: Protein A or G purified
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Test Specificity: It recognizes a polypeptide of 6.5kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60% of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy.
• Content And Storage: Store at 4C in the dark.
• Isotype: IgG1 κ

For Research Use Only